

Doç.Dr. Nebi Serkan DEMİRCİ

Kişisel Bilgiler

E-posta: nebiserkan.demirci@iuc.edu.tr

Web: <http://avesis.istanbulc.edu.tr/4321/>

Araştırma Alanları

Sağlık Bilimleri

Akademik Unvanlar / Görevler

Doç.Dr., İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2020 - Devam Ediyor

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection**
ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., TUTAR O., SAMANCI C., VELİDEDEOĞLU M., YASSA A. E. , DEMİRCİ N. S. , DEMİRELLİ F. H.
JOURNAL OF SURGICAL ONCOLOGY, 2021 (SCI İndekslerine Giren Dergi)
- II. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**
Oksuzoglu B., Esin E., Koksoy E. B. , Demirci N. S. , Sendur M. A. N. , Dede I., Sezer A., Karci E., Yildirim N., Yalcin B., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi)
- III. **Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma**
Demirci N. S. , Ozdemir N. Y. , Erdem G. U. , Bozkaya Y., Yazici O., Zengin N.
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, cilt.119, sa.3, ss.180-186, 2018 (SCI İndekslerine Giren Dergi)
- IV. **Queries for the article entitled "Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases"**
Erdem G. U. , Sahin S., Karatas F., Aytakin A., Demirci N. S. , Yazilitas D.
BREAST, cilt.36, ss.104-105, 2017 (SCI İndekslerine Giren Dergi)
- V. **Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?**
Demirci N. S. , Dogan M., Erdem G. U. , Kacar S., Turhan T., KILIÇKAP S., Cigirgan L. C. , Kayacetin E., Bozkaya Y., Zengin N.
SAUDI JOURNAL OF GASTROENTEROLOGY, cilt.23, sa.3, ss.183-189, 2017 (SCI İndekslerine Giren Dergi)
- VI. **Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.**
Erdem G. U. , Altundag K., Ozdemir N. Y. , Sahin S., Demirci N. S. , Karatas F., Bozkaya Y., Aytakin A., Tasdemir V., Aslan A. C. , et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.22, ss.365-376, 2017 (SCI Expanded İndekslerine Giren Dergi)
- VII. **Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with**

recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study
Demirci N. S. , AKSOY S., Ozdemir N. Y. , Erdem G. U. , Ozcelik M., Tanrikulu E., Eren T., Bozkaya Y., Sahin S., Basol F., et al.

CURRENT MEDICAL RESEARCH AND OPINION, cilt.33, sa.3, ss.401-407, 2017 (SCI İndekslerine Giren Dergi)

- VIII. **Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach**
Bozkaya Y., Erdem G. U. , Ozdemir N. Y. , Demirci N. S. , Hocasade C., Yazici O., Zengin N.
CURRENT MEDICAL RESEARCH AND OPINION, cilt.33, sa.1, ss.109-116, 2017 (SCI İndekslerine Giren Dergi)
- IX. **The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma**
Bozkaya Y., Dogan M., Yazici O., Erdem G. U. , Demirci N. S. , Zengin N.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, cilt.17, sa.2, ss.138-143, 2017 (SCI İndekslerine Giren Dergi)
- X. **Prognostic Effect of Symptomatic and Asymptomatic Venous Thromboembolism in Patients with Gastric Cancer**
Bozkaya Y., Ozdemir N., Demirci N. S. , Erdem G. U. , Yazici O., Arslan S., Zengin N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.27, sa.2, ss.100-109, 2017 (SCI İndekslerine Giren Dergi)
- XI. **The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer**
Yazilitas D., Ozdemir N., Yazici O., Hocasade C., Demirci N. S. , Zengin N.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.12, sa.4, ss.1257-1260, 2016 (SCI İndekslerine Giren Dergi)
- XII. **Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology**
Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S. , et al.
TUMOR BIOLOGY, cilt.36, sa.12, ss.9641-9648, 2015 (SCI İndekslerine Giren Dergi)
- XIII. **A rare case: Hallucination associated with pazopanib**
Demirci N. S. , Erdem G. U. , Dogan M., Ozdemir N. Y. , Zengin N.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.11, sa.4, ss.961-962, 2015 (SCI İndekslerine Giren Dergi)
- XIV. **Rectal Cancer With Metastasis to the Face**
Yazilitas D., Dogan M., Ileri A. B. , Ozdemir N., Demirci N. S. , Zengin N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.25, sa.2, ss.145-147, 2015 (SCI İndekslerine Giren Dergi)
- XV. **Can targeted programmed death-1 antibody be a new treatment approach in breast cancer.**
Sendur M. A. N. , Aksoy S., Demirci S., Ozdemir N. Y. , Zengin N., Altundag K.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.19, ss.584, 2014 (SCI Expanded İndekslerine Giren Dergi)
- XVI. **IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)**
Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S. , et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.8, 2013 (SCI İndekslerine Giren Dergi)

Diğer Dergilerde Yayınlanan Makaleler

- I. **The Determinants of Profitability in Manufacturing Industry Sector: Panel Data Analysis with CBRT Sectoral Balance Sheets (1996-2015)**
Demirci N. S.
EGE ACADEMIC REVIEW, cilt.17, sa.3, ss.381-393, 2017 (ESCI İndekslerine Giren Dergi)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Modified epirubicin and oxaliplatin plus capecitabine (EOX) Regimen as second-line therapy after failure of modified docetaxel and cisplatin plus fluorouracil (DCF) regimen in advanced gastric cancer**
Bozkaya Y., Yazici O., Ozdemir N., Erdem G. U., Demirci N. S., Zengin N.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28
- II. **Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.**
Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Yilmaz F. M., Kilickap S., Cigirgan L. C., Kayacetin E., Zengin N.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- III. **Modified docetaxel, cisplatin and fluorouracil therapy as a first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.**
Demirci N. S., Aksoy S., Ozdemir N., Babacan T., Erdem G. U., Bozkaya Y., Zengin N., Gullu I. H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- IV. **Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.**
Ozdemir N., Demirci N. S., Yuksel S., Erdem G. U., Odabas H., Boruban M. C., Hacibekiroglu I., Karaagac M., Ucar M., Ozturk B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- V. **Comparative study of receptor expression diversity between primary and recurrent lesions in patients with metastatic breast cancer.**
Erdem G. U., Ozdemir N., Sahin S., Demirci N. S., Karatas F., Bozkaya Y., Aytekin A., Sever A. R., Zengin N., Altundag M. K.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- VI. **Effect of adding taxane to platin-5-fluorouracil combination on survival in elderly patients with advanced gastric cancer: A retrospective-multicenter study.**
Gunaldi M., Kose F., Demirci N. S., Gundur S., Ozdemir N., Kocoglu H., OKUTURLAR Y., Sedef A. M., Erdem D., Goksu S. S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- VII. **The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fluorouracil (mDCF) regimen**
Yazici O., Ozdemir N., EREL Ö., Demirci N. S., AKSOY S., ŞENDUR M. A. N., Dogan M., Yazililas D., Erdem G. U., Neselioglu S., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- VIII. **The importance of thiol/disulphide homeostasis in patients with advanced colorectal cancer receiving modified fluorouracil and leucovorin plus oxaliplatin (mFOLFOX) regimen**
Yazici O., Dogan M., EREL Ö., Bozkaya Y., Ozdemir N., Demirci N. S., NEŞELİOĞLU S., AKSOY S., Zengin N.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- IX. **Operated and early stage ampulla vateri tumours: Prognostic assessment**
Yildirim N., Mulazimoglu E., Yuksel S., Demirci N. S., Erdem G. U., Odabas H., Ozturk B., Hacibekiroglu I., Yazici O., Karaagac M., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51
- X. **The effect of body mass index on prognosis and survival of ER(-) and PR(+) nonmetastatic breast cancer patients: Single institute experience.**
Dogan M., Erdem G. U., Demirci N. S., Zengin N.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

Atıflar

Toplam Atıf Sayısı (WOS):81

h-indeksi (WOS):6